Paradigm Shift in Management of Unresectable Hepatocellular Carcinoma (uHCC) In Hong Kong, liver cancer is the fifth most common cancer (with 1,771 new cases of liver cancer reported in 2021) and the third most common cause of cancer-related deaths ...
Chronic lymphocytic leukaemia (CLL) is a chronic lymphoproliferative disorder characterised by proliferation of monoclonal mature B-cells in peripheral blood, bone marrow, and secondary lymphoid tissues, such as spleen and lymph nodes 1 . The incide...
Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...
The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...
Reduced Overall Survival in Refractory MM Although the application of the first IMiD, lenalidomide, had significantly increased median overall survival (OS) 2 , Prof. Leleu commented that the treatment success was hindered by the refractoriness of M...
Standard Treatment Regimens for NSCLC and the Potential Challenges “Treatment goals vary across NSCLC patients at different stages of the disease. For patients at early and intermediate stages of NSCLC, they are usually treated with curative i...
T he Importance of Achieving Deepest Possible Response and Continuous Therapy While improving long-term survival for patients with MM is desirable, clinical data suggested that complete response (CR) to treatment is associated with survival outcomes...
Uncovering Psychological Burden of Advanced Prostate Cancer Psychological distress is prevalent among patients with advanced PCa as compared to those with localised disease, and the morbidity adversely affects patients’ HRQOL 4 . Essentially, ...
Poor Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer (NSCLC) NSCLC, which accounts for 80-85% of all cases of lung cancer, constitute one of the leading causes of mortality worldwide 6,7 . In approximately 30% of patients, the diseas...
Diagnostic Imaging for HCC in Local Clinical Practice Currently, local guideline on diagnostic imaging for HCC is yet to be developed, whereas various international diagnostic guidelines such as the Asian Pacific Association for the Study of the Liv...
Consolidation Therapy with Durvalumab “A revolutionary treatment of lung cancer has emerged in 2017. It is, durvalumab, a monoclonal antibody against programmed death ligand 1 (PD-L1). Physiologically, PD-L1 binds to its receptor programmed de...
